GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enwei Pharmaceutical Co Ltd (SZSE:301331) » Definitions » EV-to-Revenue

Enwei Pharmaceutical Co (SZSE:301331) EV-to-Revenue : 3.15 (As of May. 27, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Enwei Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Enwei Pharmaceutical Co's enterprise value is ¥2,415.1 Mil. Enwei Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥767.9 Mil. Therefore, Enwei Pharmaceutical Co's EV-to-Revenue for today is 3.15.

The historical rank and industry rank for Enwei Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

SZSE:301331' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.26   Med: 3.08   Max: 3.65
Current: 3.15

During the past 7 years, the highest EV-to-Revenue of Enwei Pharmaceutical Co was 3.65. The lowest was 2.26. And the median was 3.08.

SZSE:301331's EV-to-Revenue is ranked worse than
61.88% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs SZSE:301331: 3.15

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-27), Enwei Pharmaceutical Co's stock price is ¥27.25. Enwei Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥7.43. Therefore, Enwei Pharmaceutical Co's PS Ratio for today is 3.67.


Enwei Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Enwei Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enwei Pharmaceutical Co EV-to-Revenue Chart

Enwei Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - - - 3.20 3.21

Enwei Pharmaceutical Co Quarterly Data
Dec17 Dec18 Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.98 2.90 3.29 3.21 2.78

Competitive Comparison of Enwei Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Enwei Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enwei Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enwei Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Enwei Pharmaceutical Co's EV-to-Revenue falls into.



Enwei Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Enwei Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2415.117/767.867
=3.15

Enwei Pharmaceutical Co's current Enterprise Value is ¥2,415.1 Mil.
Enwei Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥767.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enwei Pharmaceutical Co  (SZSE:301331) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Enwei Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=27.25/7.43
=3.67

Enwei Pharmaceutical Co's share price for today is ¥27.25.
Enwei Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥7.43.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enwei Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Enwei Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Enwei Pharmaceutical Co (SZSE:301331) Business Description

Traded in Other Exchanges
N/A
Address
Chuangye Avenue, Enwei Building, Economic Development Zone, Aba District, Tibet Autonomous Region, Changdu, CHN, 854000
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production and sales of proprietary Chinese medicines and chemical medicines.

Enwei Pharmaceutical Co (SZSE:301331) Headlines

No Headlines